anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a medicine used for treating chronic pharyngolaryngitis and vocal cord diseases. The medicine is prepared from main materials of folium perillae, saposhnikovia divaricata, reed rhizome, balloon flower root, creeping liriope, and raw licorice. Also, weeping forsythia fruit, wild mint herb, florist dendranthema, and Chinese globe flower can be contained in the medicine. The traditional Chinese medicine formulation provided by the invention has an advantage of comfortable mouthfeel. The medicine does not hurt the spleen and stomach, and can be taken for a long term. With the medicine, throat symptoms can be effectively released, and pharyngolaryngitis can be cured. With different preparation technology, the formulation can be prepared into oral preparations such as medicinal teas, particles, tablets, pills, and oral liquids; or preparations for local application, such as buccal tablets and aerosols. The medicine provides functions of lung facilitating, sore-throat relieving, body fluid regenerating, and heat relieving. The medicine is used for treating chronic pharyngolaryngitis and vocal cord diseases.
Ivermectin Prescribing protocol: Participants were prescribed Ivermectin 12mg stat per oral and then 12 mg per oral after 12 hours and 12mg per oral after 24 hours and we looked at the response at day 7 on follow up in terms of improvement of symptoms like (Fever, Cough, sore throat, Headache, Shortness of breath, lethargy, and fatigue. and any side effects of the drugs were noted as well.
Participants in the pericapsular nerve group block (PENG) arm will receive a PENG block preoperatively in the block area placed under direct ultrasound guidance as follows: Parenteral midazolam and fentanyl will be titrated to patient comfort. Standard skin sterilization, prepping and draping will be applied to the area Anatomical landmarks identified using ultrasound and skin will be numbed using 2-3 cc of 2% lidocaine. Long acting local anesthetic, a bolus of 25 cc of 0.5 % Bupivacaine will be injected lateral to iliopubic eminence (IPE). A Curvilinear low frequency (2-5 MHz) ultrasound probe will be used to identify landmarks. A 22 G, 10 cm needle will be inserted using in-plane technique and advanced to target site (17).
There has been an increasing interest in plasmalogens as a potential therapeutic agent for age-related cognitive decline and neurodegenerative conditions, given the growing understanding of their involvement in key cellular functions as well as the clinical trends observed when plasmalogen levels are depleted. In addition to supporting the structural integrity of membranes, these plasmalogens are also involved in a variety of critically important cell functions: membrane fusion, ion transport, vesicle formation, and oxidation-reduction. Plasmalogen and serum plasmalogen deficiency has been shown to impair cellular functions, particularly related to cholesterol processing, and has been implicated in Alzheimer's and other diseases. Plasmalogen precursor supplementation has been demonstrated as safe and potentially efficacious in preclinical studies and some patient populations. In theory, ProdromeNeuro supplementation may yield therapeutic benefits among patients with age-related cognitive decline by increasing levels of neuroprotective plasmalogens.

The present study is being undertaken as an open-label study to evaluate the safety and tolerability of ProdromeNeuro Omega-3 Oil as an intervention for patients with age-related cognitive decline. Baseline and outcome measures in this study utilize validated tests that are appropriate for repeated measures. Neurocognitive assessment and serology testing kits to evaluate for plasmalogen levels will also be administered at baseline, end of the first month, end of the second month, end of the 3 month, and after one month post treatment termination.
Sleep is vital to our daily activity. Lack of proper sleep can impair functionality and overall health. While stress is known for its detrimental impact on sleep quality, the precise effect of pre-sleep stress on subsequent sleep structure remains unknown. This study introduced a novel approach to study the pre-sleep stress effect on sleep structure, specifically slow-wave sleep (SWS) deficiency. To achieve this, we selected forehead resting EEG immediately before and upon sleep onset to extract stress-related neurological markers through power spectra and entropy analysis. These markers include beta/delta correlation, alpha asymmetry, fuzzy entropy (FuzzEn) and spectral entropy (SpEn). Fifteen subjects were included in this study. Our results showed that subjects lacking SWS often exhibited signs of stress in EEG, such as an increased beta/delta correlation, higher alpha asymmetry, and increased FuzzEn in frontal EEG. Conversely, individuals with ample SWS displayed a weak beta/delta correlation and reduced FuzzEn. Finally, we employed several supervised learning models and found that the selected neurological markers can predict subsequent SWS deficiency. Our investigation demonstrated that the classifiers could effectively predict varying levels of slow-wave sleep (SWS) from pre-sleep EEG segments, achieving a mean balanced accuracy surpassing 0.75. The SMOTE-Tomek resampling method could improve the performance to 0.77. This study suggests that stress-related neurological markers derived from pre-sleep EEG can effectively predict SWS deficiency. Such information can be integrated with existing sleep-improving techniques to provide a personalized sleep forecasting and improvement solution.
The Trier Social Stress Task (TSST) is a standardized, 15-minute laboratory task designed to induce psychological stress in laboratory settings (Kirschbaum, Pirke, \& Hellhammer, 1993). The TSST consists of three continuously successive phases: (a) an anticipation period (5 min); (b) a free speech task (5 min); and (c) a mental arithmetic task (5 min). As is standard in the TSST procedure, participants were told by a research staff member that they would provide a brief speech about "their dream job" in front of a critical audience. At the end of the speech, a member of the audience instructed the participant to conduct serial subtractions as accurately and quickly as possible.
A mail order prescription system and method for a mail order pharmacy program is disclosed. The mail order prescription system and method supports enrollment and management of health benefit plan members in a mail order pharmacy program. The system and method support switching previously filled prescriptions to a mail order pharmacy program. The system and method also allow users to enter data for new, previously unfilled prescriptions. The system and method further facilitate contacting prescribing physicians and obtaining authorization for fulfillment of prescriptions by mail. In an example embodiment, users access a web portal to view prescription data for a member and to switch current prescriptions to mail order and/or to enter data for new prescriptions. Additional cost savings may be realized by allowing users to select a generic equivalent or a generic alternative instead of an original prescription.
Participants received 500 mg of Lebrikizumab (2 x 250 mg) subcutaneous (SC) injections as a loading dose at Baseline followed by 250 mg of Lebrikizumab administered SC Q4W from Week 4 until Week 12, in combination with topical corticosteroid. Week 16 responders entered maintenance period and continued with the same treatment. Week 16 non responders entered Escape Arm and received Lebrikizumab 250 mg Q2W until Week 68.
Disclosed herein are novel nucleic acid and protein sequences that are essential to fertility. In particular, human Mater cDNA and protein sequences are provided. Functional MATER is required for female fertility; zygotes that arise from Mater null oocytes do not progress beyond the two-cell stage. Methods are described for detecting an autoimmune response to MATER in a subject by detecting autoantibodies that recognize an epitope of a MATER protein. Also provided are methods for diagnosis of infertility or reduced fertility by detecting presence of MATER protein autoantibodies in a subject. The disclosure also describes kits for detecting MATER autoantibodies comprising MATER protein.
An osmotic device that, following the imbibition water vapor, provides for the controlled release of a beneficial agent to a non-aqueous environment. The device comprises a hydrophilic formulation and a beneficial agent, surrounded by a wall. The wall is formed at least in part of a semipermeable hydrophobic microporous membrane having an average pores size between about 0.1 μm and 30 μm. The pores are substantially filled with a gas phase. The hydrophobic membrane is permeable to water in the vapor phase and the hydrophobic membrane is impermeable to an aqueous medium at a pressure less than about 100 Pa. The beneficial agent is released, for example, by osmotic pumping or osmotic bursting upon imbibition of sufficient water vapor into the hydrophilic formulation. The high water fluxes attendant with these vapor-permeable hydrophobic membranes facilitate the delivery of large quantities of beneficial agents without requiring large surface areas (quantities) of hydrophobic microporous membrane. In addition, use of vapor-permeable hydrophobic microporous membranes allow osmotic devices to be used in environments having limited water availability, such as air or soil.
BACKGROUND: Objective disease activity biomarkers are lacking in chronic inflammatory demyelinating polyneuropathy (CIDP), impacting treatment decisions in clinical care and outcomes in clinical trials. Using a proximity extension assay, we aimed to identify candidate serum protein biomarkers for disease activity in CIDP.
METHOD: We collected clinical data and serum of 106 patients with CIDP. Patients starting induction treatment (n=53) and patients on maintenance treatment starting treatment withdrawal (n=40) were assessed at baseline and at 6 months (or at relapse). Patients in remission (n=13) were assessed once. Clinical disease activity was defined based on improvement or deterioration by the minimal clinically important difference on the inflammatory Rasch-built Overall Disability Scale in combination with either grip strength or the Medical Research Council sum score. Using a proximity extension assay (Olink Explore platform), 1472 protein levels were analysed in serum. Candidate proteins were selected based on fold change>0.5 or <-0.5 and p<0.05 between clinically active and inactive disease. Longitudinal changes of candidate proteins between baseline and follow-up were analysed.
RESULTS: We identified 48 candidate proteins that differed between clinically active and inactive disease on cross-sectional comparison. Five of these proteins (SUGT1, IRAK4, DCTN1, 5'-nucleotidase cytosolic IIIA (NT5C3A), glutaredoxin (GLRX)) also showed longitudinal changes consistent with disease activity changes. IRAK4 was also identified in a sensitivity analysis, using another definition for disease activity.
CONCLUSION: Our results indicate that IRAK4 and possibly SUGT1, DCTN1, NT5C3A and GLRX are candidate biomarkers for monitoring clinical disease activity in CIDP.
Subjects will receive 2 sessions of stimulation: one active and one sham tDCS on two separate visits. The order in which they receive the stimulation will be randomized. Stimulation parameters will be at 2 mA for a total of 20 minutes.
Compositions for appetite control and/or regulation or loss of weight are described. The described compositions comprise a unique combination of ingredients, the combination including at least botanical substances, amino acids, and one or more metals, and may comprise and in some embodiments do further comprise one or more vitamins and/or caffeine. The botanical substances have in combination, more than a singular biologic target, the target including at least one neurotransmitter. The compositions are provided in dry form. The dry form may be in a form suitable for a subject to take the composition by mouth. The unique combination of components in each composition provides a multi-targeted approach for the regulation and control of appetite for a subject taking the composition. The composition is preferably taken before a meal. A recommended dose includes at least one dose of the described composition per day.
For all patients without documented proven or probable invasive fungal disease (IFD), patients will receive fluconazole during the treatment in the laminar air flow units (LAF). After discharged from LAF units, patients will receive anti-mold prophylaxis in case of haplo-identical or HLA-matched unrelated donor transplantation to d+100 without active acute GVHD (aGVHD). In case of active aGVHD, the prophylaxis treatment will be extended until recovery of aGVHD and tapering of immunosuppression. In case of HLA-matched sibling donor, fluconazole will be continued to d+100 and anti-mold prophylaxis will be given in case of active aGVHD.
Kallikrein and trypsin inhibitors (I) are purified by dissolving at pH 5.5-7 in water saturated with a mineral salt, precipitating at pH 1-3, and re-dissolving at neutral pH. In example an aqs. soln. of (I) contg. 2300 KIU/ml and having a purity of 1 KIU/mu g of dry organic residue was treated with NaCl to saturate, filtered, and the filtrate adjusted to ph2. The resultant precipitate was suspended in water and adjusted to neutral pH with NaOH which caused complete soln. The resultant soln. has a purity of 1KIU/1 mu g of dry organic residue. The recovery was 95%.
BACKGROUND: This case presents a detailed forensic examination of a unique femicide case followed by the perpetrator's suicide.
CASE REPORT: On a Sunday afternoon, a 52 year old man killed his 43 year old partner in their home with eleven stab wounds. A few minutes later, he committed suicide by suspending himself to a tree in their home garden by means of a rope. This unique case is interesting because of the combination of methods used for both homicide and suicide, as well as the relationship dynamics between the victim and perpetrator. The perpetrator committed homicide by stabbing and then hanged himself.
CONCLUSION: The case adds valuable knowledge to Forensic Medicine, advocating for increased awareness and preventive measures against domestic and gender-based violence. This report provides an in-depth analysis of a homicide-suicide incident, focusing on a unique case of homicide-suicide. It serves to highlight the global crisis of femicide. The case is situated within the context of gender- based violence, illustrating how such acts are deeply rooted in societal norms. It highlights patterns of intimate partner violence, where emotional factors play a significant role. Forensic analysis uncovered the overkill nature of the homicide, indicating excessive injuries beyond what was necessary for death, reflecting the psychological turmoil of the perpetrator. It emphasizes the importance of identifying signs of potential violence in domestic settings and implementing interventions for mental health support and the prevention of genderbased violence.
The feedback group will get real neurofeedback about changes in anxiety-related cerebral hemodynamics. AI-fNIRS neurofeedback will be provided 3 times a week, for a total of 4 weeks.
A test battery (10) for patients having fluctuating movement disorder, e.g. Parkinson's disease, comprises both a motor test section (17) and a patient diary collection section (19) collecting data representing patient subjective experiences. The test battery (10) further comprises a scheduler (20), which is arranged to restrict operation of the motor test section (17) and the patient diary collection section (19) to a multitude of predetermined limited time intervals. This restriction in time provides an association in time between the two types of tests, as well as a possibility for timing the test intervals dependent on e.g. the medication schedule or the daily activity schedule. The limited time intervals are preferably shorter than or equal to one hour, and preferably there is at least one limited time interval each 24 hours. The test battery (10) is preferably implemented as a portable device, enabling monitoring under home environment conditions.
The present invention relates to medicine for treating venereal diseases, which solves the problems of long-time treatment and unobvious effect during venereal diseases treatment. The present invention is characterized in that the medicine has the following components: 3 to 20 parts by weight of stalactite powder, 1 to 11 parts by weight of cinnabar, 1 to 11 parts by weight of amber, 1 to 11 parts by weight of borneol, and 1 to 15 parts by weight of pearl. The components are mixed and pulverized, and a right amount of flour are added in the components to be prepared into a powder preparation. Then, according to preparation requirements, the mixture is prepared into capsules, or powder, or tablets, or pills. The medicine is mixed with 250g to 750g of glabrous greenbrier rhizome decocted in water to be taken; 0.1 to 10 parts of realgar, 0.1 to 10 parts of calomelas and 5 to 50 parts of almond are mixed and pulverized, and the medicine is externally applied at an afflicted part after being mixed with a right amount of pig bile. The present invention has the functions of clearing away heat and toxic materials, promoting urination, eliminating toxin along with urination, relieving uneasiness and removing toxin, and has the curative effect on various venereal diseases, such as syphilis, gonorrhea, eczema, etc. The present invention has the advantages of high medical performance, rich medicine source, low cost and no side effect. A patient can take effect without pain after the medicine is taken for several days, and the medicine can be easily accepted by patients.
NEW MATERIAL:Compounds represented by the formula (X1 and X2 are hydroxyl or oxo, X3 is H or may be oxo in case X1 is oxo; X4 is H, hydroxyl or oxo; X5 is hydroxyl or oxo, provided that X5 is hydroxyl or oxo respectively in case X4 is H or hydroxyl and oxo). EXAMPLE:4'-Hydroxy-5,5'-diisopropyl-2,2'-dimethylbiphenyl-3,4-dione. USE:An antioxidant and a deodorant. The subject compounds are the components in Thyms vulgaris Linne, i.e., a spice vegetable. PREPARATION:Thyms vulgaris Linne is dried and ground and the resultant powder is extracted with a nonpolar solvent. The obtained extracted solution is then filtered and the resultant residue is extracted with a polar solvent. The solvent of the obtained extracted solution is distilled off, thus obtaining the objective compounds of the formula as the extract.
The Prospective Malignant Ascites Alfapump® study is a single-arm, prospective study to evaluate the performance and safety of the Alfapump® system in the treatment of patients with malignant ascites. The Alfapump® system is a fully implantable programmable pump, able to move ascitic fluid from the peritoneal cavity to the bladder via 2 catheters. The Alfapump® has obtained CE (Conformité Européenne) mark approval for the indication of malignant ascites. The primary objective of the study is to assess the performance of the system to remove ascites. Secondary objectives are to evaluate the safety and tolerability of the Alfapump® in the treatment of malignant ascites for a total follow-up period of 9 months, and to evaluate quality of life (QoL) by reduction or elimination of paracentesis requirement. Furthermore the study includes an exploratory scientific objective as to feasibility to obtain 'liquid biopsy' samples suitable for analysis in a non-invasive way after Alfapump® implantation. 40 patients with malignant ascites will be enrolled in up to 8 sites in Europe (Belgium, United Kingdom, Switzerland). Specific sub-analysis of data from patients with gynecological (ovarian) cancer is planned.
Tumor necrosis factor type 1A receptor-associated periodic syndrome (TRAPS) and cryopyrin-associated autoinflammatory syndrome (CAPS) are rare monogenic autoinflammatory diseases (AIDs) mainly caused by pathogenic variations in the TNFRSF1A and NLRP3 genes, respectively. Here, we describe a unique patient presenting with symptoms overlapping both TRAPS and CAPS, without known pathogenic variants in the respective genes. The patient harbored the p.Val200Met variation in NLRP3 and the p.Ser226Cys variation in TNFRSF1A, prompting us to delve deeper into the functional analysis due to conflicting or inconclusive pathogenicity interpretations of the variants across various databases. Molecular dynamics analysis of the p.Val200Met variation in NLRP3 revealed a rigid conformation in the helical domain 2 subdomain of the NACHT domain. This increased rigidity suggests a potential mechanism by which this variation supports the assembly of the NLRP3 inflammasome. Notably, the patient's peripheral mononuclear blood cells demonstrated an elevated IL-1β response upon lipopolysaccharides (LPS) induction. Subsequent initiation of anti-IL-1β therapy resulted in a significant alleviation of the patient's symptoms, further supporting our hypothesis. We interpret these findings as suggestive of a potential pathophysiological role for the NLPR3 p.Val200Met variation in shaping the patient's clinical phenotype, which was also supported by clinical and genetic analysis of the family. This case underscores the complexity of the genetic landscape in AIDs and highlights the value of combining family genetic and functional data to refine the understanding and management of such challenging cases.
Provided is a nanosphere for delivery of a therapeutic agent comprising: a polymer matrix; discrete liquid oil droplets dispersed in the polymer matrix; and a therapeutic agent dissolved or dispersed in the oil. In some embodiments, the nanosphere is pegylated. In some embodiments, the nanosphere has a diameter of from about 100 nm to about 300 nm. In further preferred embodiments, the nanosphere has a diameter of from about 150 nm to about 250 nm. In yet further embodiments, the nanosphere has a diameter of from about 180 nm to about 220 nm. In some embodiments, the oil comprises a lipid or a phospholipid. In further embodiments, the lipid or the phospholipid has a melting point below 20° C. In some embodiments, the polymer is a natural, modified or synthetic polymer. In further embodiments, the polymer is biodegradable.
Lipid metabolic reprogramming of tumor cells has been proven to play a critical role in tumor initiation and development. However, lipid metabolism in cancer-associated fibroblasts (CAFs) has rarely been studied, particularly in CAFs of oral squamous cell carcinoma (OSCC). Additionally, the molecular mechanism by which tumor cells regulate lipid metabolism in fibroblasts is unclear. In this study, we found that phosphorylated ATP citrate lyase (p-ACLY), a key lipid metabolic enzyme, was upregulated in OSCC CAFs. Compared to paracancerous normal fibroblasts, CAFs showed enhanced lipid synthesis, such as elevated cytosolic acetyl-CoA level and accumulation of lipid droplets. Conversely, reduction of p-ACLY level blocked this biological process. In addition, blocking lipid synthesis in CAFs or inhibiting fatty acid uptake by OSCC cells reduced the promotive effects of CAFs on OSCC cell proliferation, invasion, and migration. These findings suggested that CAFs are one of lipid sources required for OSCC progression. Mechanistically, AKT signaling activation was involved in the upregulation of p-ACLY level and lipid synthesis in CAFs. Interleukin-8 (IL8), an exocrine cytokine of OSCC cells, could activate AKT and then phosphorylate ACLY in fibroblasts. This study suggested that the IL8/AKT/p-ACLY axis could be considered as a potential target for OSCC treatment.
Patients undergo total body irradiation (TBI) on days -7 to -4 and receive cyclophosphamide IV on days -3 and -2. Alternatively, patients may receive cyclophosphamide on days -7 and -6 and undergo TBI on days -4 to -1.